QC
ARCT icon

Quantedge Capital’s Arcturus Therapeutics ARCT Stock Holding History

Quantedge Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,800
Closed -$993K – 178
2024
Q2 		$993K Sell
40,800
-9,300
-19% -$282K 0.36% 73
2024
Q1 		$1.69M Buy
+50,100
New +$1.78M 0.71% 44

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantedge Capital's ARCT Position: Q3 2024 in Review

Quantedge Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 40,800 shares — an estimated $993K sold.

Quantedge Capital first reported a position in ARCT in Q1 2024 and held it in 2 quarters. The position peaked at $1.69M in Q1 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Quantedge Capital reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Quantedge Capital sold 40,800 Arcturus Therapeutics shares in Q3 2024, an estimated $993K.
  • Quantedge Capital first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 2 quarters.
  • Quantedge Capital's Arcturus Therapeutics position peaked at $1.69M in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Quantedge Capital's 13F filing for Q3 2024, filed 13 Nov 2024.